Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), has been successfully used in the treatment of refractory AIHA among chronic lymphocytic leukaemia patients (49, 50) and could be an option to consider in PID. This evidence concerns the gene BTK and pelvic inflammatory disease.